EverHint – SMA 20/50 Crossover – Top 3 Buy and Top 5 Sell Signals for Aug 21, 2026
Excerpt: 8 signals (from 19 total). Real Estate leads (4). price range $10-$379.
What This Signal Is
Detects fresh crossovers between the 20-day simple moving average (SMA20) and the 50-day simple moving average (SMA50). Uses two SMAs, making it more stable and less prone to false signals compared to EMA-based strategies. Well-suited for identifying medium-term trend changes with higher reliability.
Entry Criteria:
- Buy: SMA20 crosses above SMA50
- Sell: SMA20 crosses below SMA50
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh crossover: Detected on today's close
Holding period: 2-6 weeks | Risk level: Medium
Market Context
Equity markets are displaying broad-based strength on August 21, 2026, with all three major indices posting gains and the Dow Jones outperforming with nearly a 1% advance. This divergence — where the Dow leads the Nasdaq — suggests investors are rotating toward value-oriented and cyclical names rather than high-growth technology, a pattern that can amplify trend-following signals like the SMA20/SMA50 crossover strategy in sectors with steadier price action.
The VIX dropping to 15.13, a decline of over 5%, signals meaningfully reduced fear in the market. Lower volatility compresses intraday price swings, which generally benefits moving average strategies by reducing false breakouts and allowing cleaner trend confirmation. When the VIX is subdued, SMA crossover signals tend to carry higher follow-through probability, as momentum is less likely to be disrupted by sudden volatility spikes reversing short-term price action.
Real Estate emerging as the top sector for today's signals is particularly notable in a low-volatility, risk-on environment. Rate-sensitive sectors like Real Estate tend to attract capital when broader market sentiment stabilizes and investors seek yield with moderate risk. The current combination of positive index momentum and a calming VIX creates a supportive backdrop for trend-following signals in this sector, though traders should remain attentive to any macro shifts that could quickly reprice rate expectations and disrupt these emerging trends.
🟢 Buy Signals (3 of 3 total)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | MCap |
|---|---|---|---|---|---|
| 1 | BATRK | Atlanta Braves Holding... | Communication Services | $51.93 | $3.3B |
| 2 | FROG | JFrog Ltd. | Technology | $92.13 | $11.2B |
| 3 | OCUL | Ocular Therapeutix, Inc. | Healthcare | $11.08 | $2.4B |
🔴 Sell Signals (5 of 16 total)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | MCap |
|---|---|---|---|---|---|
| 1 | BAP | Credicorp Ltd. | Financial Services | $378.97 | $30.1B |
| 2 | BCRX | BioCryst Pharmaceutica... | Healthcare | $9.55 | $2.4B |
| 3 | DOC | Healthpeak Properties,... | Real Estate | $21.40 | $14.8B |
| 4 | EEFT | Euronet Worldwide, Inc. | Technology | $70.07 | $2.7B |
| 5 | EPRT | Essential Properties R... | Real Estate | $30.84 | $6.7B |
Field Notes
Sector concentration: Real Estate (4), Healthcare (3), Consumer Cyclical (3)
Data coverage: 0.0% insider (7d), 0.0% congressional (30d), 0.0% earnings, 26.3% news (7d)
Peer Analysis
OCUL (Ocular Therapeutix, Inc.): Leads 5 peers: QURE ($48.37), GPCR ($49.09), EWTX ($44.18), VRDN ($24.29), MESO ($17.00)
EPRT (Essential Properties Realty Trust, Inc.): Leads 5 peers: TRNO ($68.17), RITM ($10.19), RHP ($128.50), REXR ($37.23), GNL ($9.04)
EEFT (Euronet Worldwide, Inc.): Leads 5 peers: PAGS ($8.62), AVPT ($13.37), SPSC ($81.09), WRD ($6.45), BB ($8.04)
Recent Headlines
BAP (Credicorp Ltd.)
- Why Credicorp (BAP) is a Great Dividend Stock Right Now
BCRX (BioCryst Pharmaceuticals, Inc.)
- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of “Moderate Buy” from Brokerages
Vlad's Take
Today's signals: Strong sector concentration in Real Estate (4 signals) suggests sector-specific rotation.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 If this added value to your research, consider liking, sharing, or subscribing. It genuinely helps.